期刊
PROTEOMICS CLINICAL APPLICATIONS
卷 7, 期 1-2, 页码 91-108出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.201200104
关键词
Biomarker discovery; Experimental autoimmune encephalomyelitis; MS; Multiple sclerosis; Quantitative proteomics
资金
- Multiple Sclerosis Research Australia (MSRA) Postgraduate Research Scholarship
- Teva Pharmaceuticals
Multiple sclerosis is an inflammatory-mediated demyelinating disorder most prevalent in young Caucasian adults. The various clinical manifestations of the disease present several challenges in the clinic in terms of diagnosis, monitoring disease progression and response to treatment. Advances in MS-based proteomic technologies have revolutionized the field of biomarker research and paved the way for the identification and validation of disease-specific markers. This review focuses on the novel candidates discovered by the application of quantitative proteomics to relevant disease-affected tissues in both the human context and within the animal model of the disease known as experimental autoimmune encephalomyelitis. The role of targeted MS approaches for biomarker validation studies, such as multiple reaction monitoring will also be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据